Search

TOPIC 277 PHASE II; COMPANION DIAG: PREDICTIVE AND PROGNOSTIC TEST ENABLING PERSO

Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: Not Available

PictureRx: Improving Medication Safety in Health Disparity Populations

Company: SAI INTERACTIVE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: Abstract Medication safety is an important concern in hospital Emergency Departments (EDs), which provide approximately 136 million patient visits annually in the US and are a common site of care for health disparity populations. In more than one-third ofED visits, patients are unable to provide an… more

Development of an Atmospheric Plasma Applicator to Treat Chronic Wounds

Company: ADVANCED PLASMA PRODUCTS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Annually, 5 to 7 million Americans are treated for chronic wounds that arise from diabetes, lower extremity arterial disease, lower extremity venous disease, pressure ulcers, and traumatic injuries, including burns, demonstrating the need for new advanced… more

Expressing bacterial bioluminescence in human cell lines: Engineering autobiolumi

Company: 490 BIOTECH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals Project Summary This Small Business Innovation Research Phase I projectproposes to engineer an autobioluminescent… more

Optimization of Rotavirus Vaccine Production

Company: Meridian Life Sciences, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Rotavirus is the most common cause of debilitating diarrhea, dehydration and death in infants and young children around the globe. Currently approved live oral vaccines (Rotarix® and RotaTeq®) are only -50% or less effective in children from developing countries. This reduced efficacy is due to… more

OTHER FUNCTIONS DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR ALK MUTATIONS.

Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: Constitutively activated forms of ALK caused by genetic aberrations have been shown to cause an expanding variety of human cancers. The FDA recently approved the Pfizer drug Xalkori (crizotinib) to treat patients with non-small cell lung cancers (NSCLC) that express ALK. Numerous other… more

IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)

Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: Lung cancer is the main cause of cancer mortality worldwide with 80% non-small cell lung cancer (NSCLC) in type and mainly driven by three mutually exclusive oncogenes, EGFR, KRAS and ALK (collectively between 30-60% of all NSCLC cases). Oncogenic driverssuch as ROS1 and RET fusions and DEPDC1… more

Atmospheric Plasma Processing to Kill Pathogens and Extend Shelf Life of Produce

Company: ADVANCED PLASMA PRODUCTS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): This SBIR Phase I project will design, build, and test the Atmospheric Plasma Produce Disinfection System (APPDS), an in-line processing unit that will operate continuously to treat fresh produce. The APPDS will reducethe risk of foodborne infections by… more

Germanium Gamma Cameras

Company: PHDS COMPANY Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: DESCRIPTION (provided by applicant): Germanium gamma-ray imaging detectors will improve the quality of in-vivo molecular-imaging applications. The objective of this program is the development of the Germanium Gamma Cameras (GGCs) as modular component detector heads suitable for convenient… more

Reducing Stroke by a Novel, Clot-dissolving Antibody

Company: TRANSLATIONAL SCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to the economy are 57.9 billion. The vast majority of acute ischemic strokes are caused by a thrombus… more

Trimer-Tag: A Technology for Producing Trivalent Biologics

Company: GENHUNTER CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): One of the modern strategies for treating autoimmune diseases such as rheumatoid arthritis and psoriasis involves the use of biologic TNF receptor decoys, such as soluble receptors or therapeutic antibodies, to intercept the inflammatory ligand TNF-1, and thus… more

Wheelchair Drive System

Company: MAX MOBILITY Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Wheelchair Drive System Over half of the wheelchair user population has developed upper extremity (UE) pain and injury. One of the activities that likely contribute to the development of injury is wheelchair propulsion. A number of technologies have been… more

TAS::75 0849::TAS

Company: RXBIO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: No satisfactory medical interventions for radiation enteritis are available yet. We have demonstrated that polyamine inhibition by a-difluoromethylornithine orDFMO, a selective and irreversible inhibitor of ornithine decarboxylase (ODC, the primary rate-limiting enzyme in the production of… more

Molded Hydrogel Tympanic Membrane Repair Constructs

Company: GRACE MEDICAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Tympanic membrane perforations are commonly seen in otology practices and about 150,000 repair surgeries are performed each year in the United States. Current office-based procedures such as paper patch tympanoplasty are relatively ineffective or, like the… more

Development of an Atmospheric Plasma Applicator to Treat Chronic Wounds

Company: ADVANCED PLASMA PRODUCTS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Annually, 5 to 7 million Americans are treated for chronic wounds that arise from diabetes, lower extremity arterial disease, lower extremity venous disease and edema, and pressure ulcers, and traumatic injuries, including burns. There is a real need for new… more

Germanium Gamma Cameras

Company: PHDS COMPANY Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Germanium gamma-ray imaging detectors will improve the quality of in-vivo molecular-imaging applications. The objective of this program is the development of the Germanium Gamma Cameras (GGCs) as modular component detector heads suitable for convenient… more

Reducing Stroke by a Novel, Clot-dissolving Antibody

Company: TRANSLATIONAL SCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to the economy are 57.9 billion. The vast majority of acute ischemic strokes are caused by a thrombus… more

High Throughput, Label-Fee Molecular Interaction Platform for Membrane Protein

Company: MOLECULAR SENSING, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Molecular interactions form the basis of healthy metabolism as well as the manifestation of disease, and comprise the very foundation of drug treatment. Tools available to study molecular interactions in their nascent environment and physiological concentrations… more

TAS::75 0894::TAS SBIR PHASE II - IDENTIFICATION OF ALCOHOL-RELEVANT MIRNA BIOMARKERS

Company: GENOME EXPLORATIONS INC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: Alcohol abuse and its related health effects are estimated to have an economic cost in the US that approaches $200 Billion per year. However, current tests for alcohol use/abuse are not reliable except when administered within several hours of intoxication. Moreover, current clinical tests for… more

Companion Diagnostic for ALK Mutations

Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: Kinase inhibitors such as Gleevec and Tarceva have markedly improved cancer therapy. Essential to the use of such inhibitors are companion diagnostics enabling determination of the mutational status of th eir kinase targets in tumors. Anaplastic lymphoma kinase (ALK) fusion oncogenes have emerged… more

PlainLanguageRx: Improving Medication Labels to Reduce Health Disparities

Company: SAI INTERACTIVE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Summary Overall, 36% of adult Americans, and 66% of Latinos, lack the level of health literacy needed to understand prescription drug information, such as the dosing instructions on medication container labels. Low hea lth literacy and poor understanding of… more

Wheelchair Drive System

Company: MAX MOBILITY Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Wheelchair Drive System Over half of the wheelchair user population has developed upper extremity (UE) pain and injury. One of the activities that likely contribute to the development of injury is wheelchair propulsion . A number of technologies have been… more

LUMINESCENT ANTIVIRAL DRUG DISCOVERY ASSAY

Company: SCI-TEC, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The goal of this SBIR Phase I project is the development of a new drug discovery platform for screening new inhibitors of viral polymerases and for studying mechanisms of action of the prospective pharmaceutical compoun ds. The main innovation in this project is… more

ENZYMATIC LUMINESCENCE microRNA ASSAY

Company: SCI-TEC, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2
Abstract: DESCRIPTION (provided by applicant): The goal of this project is to develop a new highly sensitive and cost effective RNA Enzymatic Luminescence Assay (qELA) for high-throughput detection and quantification of microRNA in biological samples. The assay impl ements the same detection concept known… more

PictureRx: An Intervention to Reduce Latino Health Disparities

Company: SAI INTERACTIVE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: DESCRIPTION (provided by applicant): Major health disparities in chronic disease control and outcomes exist among Latinos, the fastest growing segment of the U.S. population. If these disparities continue, demographic trends will magnify their adverse heal th, societal, and economic impact. Chronic… more